Magnetic Resonance-Guided Radiotherapy Using an Integrated Magnetic Resonance Linear Accelerator (MRL)

Summary

Advances in radiotherapy are closely tied to imaging technology, with a new system combining a 1.5T MRI and a linear accelerator (MR-LINAC) now available. This system, used in a few centers worldwide, offers better soft tissue imaging and daily adjustments for more accurate treatment. The Calgary Cancer Centre, set to open in late 2024, will be the only cancer center in Canada with two MR-LINAC machines, potentially improving cancer control and reducing side effects. However, it is complex and resource-intensive, requiring specialized training. The system enables daily adaptive treatments based on MRI scans, better targeting tumors while protecting surrounding organs. Over time, increased experience and automation are expected to streamline these processes. The primary goal is to understand where MR-LINAC improves outcomes and develop efficient, cost-effective treatments.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 120

Accepts healthy participants: Yes

Inclusion criteria:

- Patients 18 years or older with a diagnosis of cancer, regardless of clinical site or stage
- Planned to receive a course of MR-guided adaptive radiotherapy using the MR-LINAC
- Ability to provide informed consent

Participate

Fill out the following form if you want to participate in this research

Method of contact

UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is committed to ensuring the privacy of all students, staff, and community members. Your personal information is being collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used and disclosed for the purposes outlined in UCalgary’s Notice of Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s Privacy Management Program. Your personal information may be input into automated systems to generate content or make decisions, recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection, use, or disclosure of your personal information, please contact accessandprivacy@ucalgary.ca.

Additional information

Contact information

Sangjune Laurence Lee, MD, FRCPC Division of Radiation Oncology, University of Calgary, Arthur J.E. Child Comprehensive Cancer Centre (CCC) 3395 Hospital Dr NW, Calgary, AB T2N 4N1 Ph: 403-521-3164, Fax: 403-283-1651

Principal investigator:

Sangjune Lee

Clinical trial:

No

REB-ID:

HREBA.CC-24-0311